ID   HAC-2
AC   CVCL_8354
SY   HAC 2; Hac2
DR   cancercelllines; CVCL_8354
DR   Cosmic; 877480
DR   Cosmic; 931363
DR   Cosmic; 945375
DR   Cosmic; 1152560
DR   Cosmic; 2582795
DR   JCRB; JCRB1359
DR   JCRB; JCRB1539
DR   JCRB; NIHS0567
DR   Wikidata; Q54872301
RX   CelloPub=CLPUB00045;
RX   PubMed=8980248;
RX   PubMed=25846456;
RX   PubMed=28196595;
WW   https://tcpaportal.org/mclp/
CC   Part of: MD Anderson Cell Lines Project.
CC   Population: Japanese.
CC   Doubling time: 46.8 hours (CelloPub=CLPUB00045).
CC   Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Unspecified (PubMed=25846456).
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Discontinued: JCRB; NIHS0567; true.
CC   Derived from site: Metastatic; Ascites; UBERON=UBERON_0007795.
ST   Source(s): JCRB
ST   Amelogenin: X
ST   CSF1PO: 12
ST   D13S317: 8,9
ST   D16S539: 10,11
ST   D5S818: 12,13
ST   D7S820: 9,11
ST   TH01: 7
ST   TPOX: 11
ST   vWA: 14,16
DI   NCIt; C40078; Ovarian clear cell adenocarcinoma
DI   ORDO; Orphanet_398971; Clear cell adenocarcinoma of the ovary
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   52Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 21
//
RX   CelloPub=CLPUB00045;
RA   Nishida M., Iwasaki H.;
RT   "Establishment of a human ovarian clear cell carcinoma cell line (HAC-2
RT   cells) in vitro.";
RL   Hum. Cell 1:345-346(1988).
//
RX   PubMed=8980248; DOI=10.1002/(SICI)1097-0215(19961220)69:6<466::AID-IJC8>3.0.CO;2-2;
RA   Ichikawa Y., Yoshida S., Koyama Y., Hirai M., Ishikawa T., Nishida M.,
RA   Tsunoda H., Kubo T., Miwa M., Uchida K.;
RT   "Inactivation of p16/CDKN2 and p15/MTS2 genes in different
RT   histological types and clinical stages of primary ovarian tumors.";
RL   Int. J. Cancer 69:466-470(1996).
//
RX   PubMed=25846456; DOI=10.3892/ijo.2015.2951;
RA   Takenaka M., Saito M., Iwakawa R., Yanaihara N., Saito M., Kato M.,
RA   Ichikawa H., Shibata T., Yokota J., Okamoto A., Kohno T.;
RT   "Profiling of actionable gene alterations in ovarian cancer by
RT   targeted deep sequencing.";
RL   Int. J. Oncol. 46:2389-2398(2015).
//
RX   PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005;
RA   Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P.,
RA   Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L.,
RA   Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D.,
RA   Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B.,
RA   Liang H.;
RT   "Characterization of human cancer cell lines by reverse-phase protein
RT   arrays.";
RL   Cancer Cell 31:225-239(2017).
//